Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury

Journal of Neurochemistry

Volumn 134, Issue 2, 2015, Pages 340-353

  Gao, Yang ^a   Xu, Siyi ^a   Cui, Zhenwen ^a   Zhang, Mingkun ^a   Lin, Yingying ^a   Cai, Lei ^b   Wang, Zhugang ^b   Luo, Xingguang ^c   Zheng, Yan ^a   Wang, Yong ^a   Luo, Qizhong ^a   Jiang, Jiyao ^a   Neale, Joseph H ^d   Zhong, Chunlong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Research Center for Model Organisms   (China)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GEORGETOWN UNIVERSITY   (United States)

Author keywords

behavior; gene knockout; Glutamate carboxypep tidase II; histopathology; N acetylaspartylglutamate; traumatic brain injury

Indexed keywords

GLUTAMATE CARBOXYPEPTIDASE II; N ACETYLASPARTYLGLUTAMIC ACID;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BEAM WALKING TEST; BRAIN DEVELOPMENT; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME ACTIVITY; EXON; EXPERIMENTAL LOCOMOTOR ACTIVITY TEST; FEMALE; GCPII GENE; GENE DELETION; GENE INACTIVATION; HIPPOCAMPAL CA2 REGION; HIPPOCAMPAL CA3 REGION; HISTOPATHOLOGY; INJURY SEVERITY; LONG TERM MEMORY; MALE; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOTOR PERFORMANCE; MOUSE; NERVE CELL DEGENERATION; NERVE CELL LESION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPATIAL LEARNING; SPATIAL MEMORY; TRAUMATIC BRAIN INJURY; WILD TYPE; ANIMAL; BRAIN INJURY; DEFICIENCY; DISEASE MODEL; ENZYMOLOGY; GENETICS; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; PATHOLOGY; PHYSIOLOGY;

MUS;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN INJURIES; DISEASE MODELS, ANIMAL; GLUTAMATE CARBOXYPEPTIDASE II; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT;

EID: 84936771154     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.13123     Document Type: Article

References (66)

1. Bacich D. J., Pinto J. T., Tong W. P., and, Heston W. D., (2001) Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm. Genome 12, 117-123.
2. Bacich D. J., Ramadan E., O'Keefe D. S., et al,. (2002) Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J. Neurochem. 83, 20-29.
3. Bacich D. J., Wozniak K. M., Lu X. C., O'Keefe D. S., Callizot N., Heston W. D., and, Slusher B. S., (2005) Mice lacking glutamate carboxypeptidase II are protected from peripheral neuropathy and ischemic brain injury. J. Neurochem. 95, 314-323.
4. Bařinka C., Rojas C., Slusher B., and, Pomper M., (2012) Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer. Curr. Med. Chem. 19, 856-870.
5. Berger U. V., Luthi-Carter R., Passani L. A., Elkabes S., Black I., Konradi C., and, Coyle J. T., (1999) Glutamate ypeptidase II is expressed by astrocytes in the adult rat nervous system. J. Comp. Neurol. 415, 52-64.
6. Bzdega T., Crowe S. L., Ramadan E. R., Sciarretta K. H., Olszewski R. T., Ojeifo O. A., Rafalski V. A., Wroblewska B., and, Neale J. H., (2004) The cloning and characterization of a second brain enzyme with NAAG peptidase activity. J. Neurochem. 89, 627-635.
7. Cao P., Liang Y., Gao X., Zhao M. G., and, Liang G. B., (2013) Administration of MS-275 improves cognitive performance and reduces cell death following traumatic brain injury in rats. CNS Neurosci. Ther. 19, 337-345.
8. Carter R. E., Feldman A. R., and, Coyle J. T., (1996) Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc. Natl Acad. Sci. USA 93, 749-753.
9. Cassidy M., and, Neale J. H., (1993) N-acetylaspartylglutamate catabolism is achieved by an enzyme on the cell surface of neurons and glia. Neuropeptides 24, 271-278.
10. Chang S. S., O'Keefe D. S., Bacich D. J., Reuter V. E., Heston W. D., and, Gaudin P. B., (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 5, 2674-2681.
11. Chopra M., Yao Y., Blake T. J., Hampson D. R., and, Johnson E. C., (2009) The neuroactive peptide N-acetylaspartylglutamate is not an agonist at the metabotropic glutamate receptor subtype 3 of metabotropic glutamate receptor. J. Pharmacol. Exp. Ther. 330, 212-219.
12. Crawley J. N., (2008) Behavioral phenotyping strategies for mutant mice. Neuron 57, 809-818.
13. Crawley J. N., and, Paylor R., (1997) A proposed test battery and constellations of specific behavioral paradigms to investigate the behavioral phenotypes of transgenic and knockout mice. Horm. Behav. 31, 197-211.
14. Dixon C. E., Lyeth B. G., Povlishock J. T., Findling R. L., Hamm R. J., Marmarou A., Young H. F., and, Hayes R. L., (1987) A fluid percussion model of experimental brain injury in the rat. J. Neurosurg. 67, 110-119.
15. Dvela-Levitt M., Ami H. C., Rosen H., Shohami E., and, Lichtstein D., (2014) Ouabain improves functional recovery following traumatic brain injury. J. Neurotrauma, 31, 1942-1947.
16. Ekmark-Lewén S., Lewén A., Israelsson C., Li G. L., Farooque M., Olsson Y., Ebendal T., and, Hillered L., (2010) Vimentin and GFAP responses in astrocytes after contusion trauma to the murine brain. Restor. Neurol. Neurosci 28, 311-321.
17. Feng J. F., Van K. C., Gurkoff G. G., et al,. (2011) Post-injury administration of NAAG peptidase inhibitor prodrug, PGI-02776, in experimental TBI. Brain Res. 1395, 62-73.
18. Feng J. F., Gurkoff G. G., Van K. C., Song M., Lowe D. A., Zhou J., and, Lyeth B. G., (2012) NAAG peptidase inhibitor reduces cellular damage in a model of TBI with secondary hypoxia. Brain Res. 1469, 144-152.
19. Fricker A. C., Mok M. H., de la Flor R., Shah A. J., Woolley M., Dawson L. A., and, Kew J. N., (2009) Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR. Neuropharmacology 56, 1060-1067.
20. Ghadge G. D., Slusher B. S., Bodner A., et al,. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl Acad. Sci. USA 100, 9554-9559.
21. Guerriero R. M., Giza C. C., and, Rotenberg A., (2015) Glutamate and GABA imbalance following traumatic brain injury. Curr. Neurol. Neurosci. Rep. 15, 545.
22. Gurkoff G. G., Feng J. F., Van K. C., Izadi A., Ghiasvand R., Shahlaie K., Song M., Lowe D. A., Zhou J., and, Lyeth B. G., (2013) NAAG peptidase inhibitor improves motor function and reduces cognitive dysfunction in a model of TBI with secondary hypoxia. Brain Res. 1515, 98-107.
23. Han L., Picker J. D., Schaevitz L. R., Tsai G., Feng J., Jiang Z., Chu H. C., Basu A. C., Berger-Sweeney J., and, Coyle J. T., (2009) Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse 63, 625-635.
24. Hlouchová K., Barinka C., Klusak V., Sacha P., Mlcochova P., Majer P., Rulisek L., and, Konvalinka J., (2007) Biochemical characterization of human glutamate carboxypeptidase III. J. Neurochem. 101, 682-696.
25. Israeli R. S., Powell C. T., Fair W. R., and, Heston W. D., (1993) Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53, 227-230.
26. Jackson P. F., Cole D. C., Slusher B. S., Stetz S. L., Ross L. E., Donzanti B. A., and, Trainor D. A., (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J. Med. Chem. 39, 619-622.
27. Janczura K. J., Olszewski R. T., Bzdega T., Bacich D. J., Heston W. D., and, Neale J. H., (2013) NAAG peptidase inhibitors and deletion of NAAG peptidase gene enhance memory in novel object recognition test. Eur. J. Pharmacol. 701, 27-32.
28. Kozikowski A. P., Zhang J., Nan F., Petukhov P. A., Grajkowska E., Wroblewski J. T., Yamamoto T., Bzdega T., Wroblewska B., and, Neale J. H., (2004) Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J. Med. Chem. 47, 1729-1738.
29. Kunkler P. E., and, Kraig R. P., (1997) Reactive astrocytosis from excitotoxic injury in hippocampal organ culture parallels that seen in vivo. J. Cereb. Blood Flow Metab. 17, 26-43.
30. Liu P., Jenkins N. A., and, Copeland N. G., (2003) A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13, 476-484.
31. Marmiroli P., Slusher B., and, Cavaletti G., (2012) Tissue distribution of glutamate carboxypeptidase II (GCPII) with a focus on the central and peripheral nervous system. Curr. Med. Chem. 19, 1277-1281.
32. McKinzie D. L., Li T. K., McBride W. J., and, Slusher B. S., (2000) NAALADase inhibition reduces alcohol consumption in the alcohol-preferring (P) line of rats. Addict. Biol. 5, 411-416.
33. Morris R. G., Garrud P., Rawlins J. N., and, O'Keefe J., (1982) Place navigation impaired in rats with hippocampal lesions. Nature 297, 681-683.
34. Nagel J., Belozertseva I., Greco S., Kashkin V., Malyshkin A., Jirgensons A., Shekunova E., Eilbacher B., Bespalov A., and, Danysz W., (2006) Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain-relation to brain concentration. Neuropharmacology 51, 1163-1171.
35. Neale J. H., (2011) N-acetylaspartylglutamate is an agonist at mGluR3 in vivo and in vitro. J. Neurochem. 119, 891-895.
36. Neale J. H., Bzdega T., and, Wroblewska B., (2000) N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 75, 443-452.
37. Neale J. H., Olszewski R. T., Gehl L. M., Wroblewska B., and, Bzdega T., (2005) The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. Trends Pharmacol. Sci. 26, 477-484.
38. Neale J. H., Olszewski R. T., Zuo D., Janczura K. J., Profaci C. P., Lavin K. M., Madore J. C., and, Bzdega T., (2011) Advances in understanding the peptide neurotransmitter NAAG and appearance of a new member of the NAAG neuropeptide family. J. Neurochem. 118, 490-498.
39. Olszewski R. T., Bukhari N., Zhou J., et al,. (2004) NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR. J. Neurochem. 89, 876-885.
40. Olszewski R. T., Wegorzewska M. M., Monteiro A. C., Krolikowski K. A., Zhou J., Kozikowski A. P., Long K., Mastropaolo J., Deutsch S. I., and, Neale J. H., (2008) Phencyclidine and dizocilpine induced behaviors reduced by N-acetylaspartylglutamate peptidase inhibition via metabotropic glutamate receptors. Biol. Psychiatry 63, 86-91.
41. Olszewski R. T., Bzdega T., and, Neale J. H., (2012a) mGluR3 and not mGluR2 receptors mediate the efficacy of NAAG peptidase inhibitor in validated model of schizophrenia. Schizophr. Res. 136, 160-161.
42. Olszewski R. T., Janczura K. J., Ball S. R., et al,. (2012b) NAAG peptidase inhibitors block cognitive deficit induced by MK-801 and motor activation induced by d-amphetamine in animal models of schizophrenia. Transl. Psychiatry 31, e145.
43. Popik P., Kozela E., Wrobel M., Wozniak K. M., and, Slusher B. S., (2003) Morphine tolerance and reward but not expression of morphine dependence are inhibited by the selective glutamate carboxypeptidase II (GCP II, NAALADase) inhibitor, 2-PMPA. Neuropsychopharmacology 28, 457-467.
44. Rahn K. A., Watkins C. C., Alt J., et al,. (2012) Inhibition of glutamate carboxypeptidase II (GCPII) activity as a treatment for cognitive impairment in multiple sclerosis. Proc. Natl Acad. Sci. USA 109, 20101-20106.
45. Robinson M. B., Blakely R. D., Couto R., and, Coyle J. T., (1987) Hydrolysis of the brain dipeptideN-acetyl-L-aspartyl-L-glutamate. J. Biol. Chem. 262, 14498-14506.
46. Romei C., Raiteri M., and, Raiteri L., (2013) Glycine release is regulated by metabotropic glutamate receptors sensitive to mGluR2/3 ligands and activated by N-acetylaspartylglutamate (NAAG). Neuropharmacology 66, 311-316.
47. Singleton R. H., Yan H. Q., Fellows-Mayle W., and, Dixon C. E., (2010) Resveratrol attenuates behavioral impairments and reduces cortical and hippocampal loss in a rat controlled cortical impact model of traumatic brain injury. J. Neurotrauma 27, 1091-1099.
48. Slusher B. S., Vornov J. J., Thomas A. G., et al,. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5, 1396-1402.
49. Slusher B. S., Thomas A., Paul M., Schad C. A., and, Ashby C. R., Jr, (2001) Expression and acquisition of the conditioned place preference response to cocaine in rats is blocked by selective inhibitors of the enzyme N-acetylated-alpha-linked-acidic dipeptidase (NAALADASE). Synapse 41, 22-28.
50. Thomas A. G., Olkowski J. L., and, Slusher B. S., (2001a) Neuroprotection afforded by NAAG and NAALADase inhibition requires glial cells and metabotropic glutamate receptor activation. Eur. J. Pharmacol. 426, 35-38.
51. Thomas A. G., Liu W., Olkowski J. L., Tang Z., Lin Q., Lu X. C., and, Slusher B. S., (2001b) Neuroprotection mediated by glutamate carboxypeptidase II (NAALADase) inhibition requires TGF-beta. Eur. J. Pharmacol. 430, 33-40.
52. Tsai G., Dunham K. S., Drager U., Grier A., Anderson C., Collura J., and, Coyle J. T., (2003) Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. Synapse 50, 285-292.
53. Vornov J. J., Wozniak K. M., Wu Y., Rojas C., Rais R., and, Slusher B. S., (2013) Pharmacokinetics and pharmacodynamics of the glutamate carboxypeptidase II inhibitor 2-MPPA show prolonged alleviation of neuropathic pain through an indirect mechanism. J. Pharmacol. Exp. Ther. 346, 406-413.
54. Wolfer D. P., Stagljar-Bozicevic M., Errington M. L., and, Lipp H. P., (1998) Spatial memory and learning in transgenic mice: fact or artifact? News Physiol. Sci. 13, 118-123.
55. Wozniak K. M., Rojas C., Wu Y., and, Slusher B. S., (2012a) The role of glutamate signaling in pain processes and its regulation by GCP II inhibition. Curr. Med. Chem. 19, 1323-1334.
56. Wozniak K. M., Wu Y., Vornov J. J., Lapidus R., Rais R., Rojas C., Tsukamoto T., and, Slusher B. S., (2012b) The orally active glutamate carboxypeptidase II inhibitor E2072 exhibits sustained nerve exposure and attenuates peripheral neuropathy. J. Pharmacol. Exp. Ther. 343, 746-754.
57. Yamada T., Zuo D., Yamamoto T., Olszewski R. T., Bzdega T., Moffett J. R., and, Neale J. H., (2012) NAAG peptidase inhibition in the periaqueductal gray and rostral ventromedial medulla reduces flinching in the formalin model of inflammation. Mol. Pain. 8, 67.
58. Yamamoto T., Nozaki-Taguchi N., Sakashita Y., and, Inagaki T., (2001) Inhibition of spinal N-acetylated-alpha-linked acidic dipeptidase produces an antinociceptive effect in the rat formalin test. Neuroscience 102, 473-479.
59. Yamamoto T., Hirasawa S., Wroblewska B., Grajkowska E., Zhou J., Kozikowski A., Wroblewski J., and, Neale J. H., (2004) Antinociceptive effects of N-acetylaspartylglutamate (NAAG) peptidase inhibitors ZJ-11, ZJ-17 and ZJ-43 in the rat formalin test and in the rat neuropathic pain model. Eur. J. Neurosci. 20, 483-494.
60. Zhao X., Ahram A., Muizelaar J. P., Berman R. F., and, Lyeth B. G., (2003) Early loss of astrocytes after experimental traumatic brain injury. Glia 44, 140-152.
61. Zhong C., Zhao X., Sarva J., Kozikowski A., Neale J. H., and, Lyeth B. G., (2005) NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. J. Neurotrauma 22, 266-276.
62. Zhong C., Zhao X., Van K. C., et al,. (2006) NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. J. Neurochem. 97, 1015-1025.
63. Zhong C., Luo Q., and, Jiang J., (2014) Blockade of N-acetylaspartylglutamate peptidases: a novel protective strategy for brain injuries and neurological disorders. Int. J. Neurosci. 124, 867-873.
64. Zhou J., Neale J. H., Pomper M. G., and, Kozikowski A. P., (2005) NAAG peptidase inhibitors and their potential for diagnosis and therapy. Nat. Rev. Drug. Discov. 4, 1015-1026.
65. Zuo D., Bzdega T., Olszewski R. T., Moffett J. R., and, Neale J. H., (2012) Effects of N-acetylaspartylglutamate (NAAG) peptidase inhibition on release of glutamate and dopamine in prefrontal cortex and nucleus accumbens in phencyclidine model of schizophrenia. J. Biol. Chem. 287, 21773-21782.
66. Zwienenberg M., Gong Q. Z., Berman R. F., Muizelaar J. P., and, Lyeth B. G., (2001) The effect of groups II and III metabotropic glutamate receptor activation on neuronal injury in a rodent model of traumatic brain injury. Neurosurgery 48, 1119-1126.